{"id":382316,"date":"2020-11-16T16:36:28","date_gmt":"2020-11-16T21:36:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=382316"},"modified":"2020-11-16T16:36:28","modified_gmt":"2020-11-16T21:36:28","slug":"neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/","title":{"rendered":"Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum"},"content":{"rendered":"<div class=\"mw_release\">\n<p>VANCOUVER, Nov.  16, 2020  (GLOBE NEWSWIRE) &#8212; via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BOd0PM2dqmeEu3kPYRgNePAkc1VXzjCV2iY6x-slPQm8xX3Aqklm5DEyepHFV7xX3HCfPq9igb3Y2bVAmhWUai9C6P69xLuTlfnUowrYGtM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>NewMediaWire<\/u><\/a> \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UzV39uceFHY2WWMJFhoYpqr2QVqugGT9VX3VujU3DwXmx72Qf8-FjE3Zy_m-gR0nTTS5Q4O8lWwwx_JM3-FzaA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Neovasc, Inc.<\/a>\u00a0(<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9iun23UAr_nqGCabST4EGyjDDYyhouPJvi10QoMqd0-n2IZH1ArgoTSLqaWHIpWy2U8zsejqRYKaikVCwcQUw8ceZvsQQ4Cz83afa0aMAiM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">NASDAQ<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gmfyJlPc2prJTBmAyaCjrLnuMfhL_R3dLfKFGJ8QUZDWcA-O_S2KP0vFIWK_KsjJdGFEZymqK-sgBQ_xc9LaBvfBLSpELKvulKG--8AddoOpegZ1u1UB4_WqkSHGvg7s\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">TSX<\/a>: NVCN), today announced that company management will be participating in the Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum on Thursday, November 19, 2020.\u00a0 Fred Colen, Neovasc\u2019s President and Chief Executive Officer, will deliver a presentation at 11:00 am EST.\u00a0 Mr. Colen will also be joined by Chief Financial Officer Chris Clark, and Chief Operating Officer Bill Little, for investor meetings throughout the day.<\/p>\n<p>A link to the live webcast of the presentation will be available online from the investor relations section of the Neovasc website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pJKGmahOWMgVMlYEfcVeF1BSOymwtvVMjyKJhrMFM_YBwW-Vz14nNSASDgMLqOkhR2xtFrSSYbIQF7_Wa639KHOxPTPmLCbeueLCUG2EWwmtYfJCMdTRISgzV6U8vXOD\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.neovasc.com\/investors\/<\/a><\/p>\n<p align=\"start\">\n        <b>About Neovasc Inc.<\/b>\n      <\/p>\n<p align=\"start\">Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer\u2122, for the treatment of refractory angina, which is not currently commercially available in the United States (2 U.S. patients have been treated under Compassionate Use) and has been commercially available in Europe since 2015, and Tiara\u2122, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kV5NFlGQqv6U4dOGPC-xezoW7d0t_9MHf_U0WojupOkb5BsPvZm2wTJ9EwvJsfHBvz99s3hh1pGuJi09Dz8_UQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.neovasc.com<\/a>.<\/p>\n<p>\n        <b><br \/>\n          <u>Investors<\/u><br \/>\n        <\/b>\n      <\/p>\n<p align=\"start\">Mike Cavanaugh<\/p>\n<p align=\"start\">Westwicke\/ICR<\/p>\n<p align=\"start\">Phone: +1.646.877.9641<\/p>\n<p align=\"start\">Mike.Cavanaugh@westwicke.com<\/p>\n<p>\n        <b><br \/>\n          <u>Media<\/u><br \/>\n        <\/b>\n      <\/p>\n<p align=\"start\">Sean Leous<\/p>\n<p align=\"start\">Westwicke\/ICR<\/p>\n<p align=\"start\">Phone: +1.646.677.1839<\/p>\n<p align=\"start\">Sean.Leous@icrinc.com<\/p>\n<p>\n        <b>Forward-Looking Statement Disclaimer<\/b>\n      <\/p>\n<p>Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact.\u00a0 When used herein, the words &#8220;expect&#8221;, &#8220;anticipate&#8221;, &#8220;estimate&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;intend,&#8221; &#8220;believe&#8221;, and similar expressions, are intended to identify forward-looking statements.\u00a0 Forward-looking statements may involve, but are not limited to, expectations as to the future growth of the Company, the expansion of its product range and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances.\u00a0 Many factors could cause the Company&#8217;s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the &#8220;Risk Factors&#8221; section of the Company&#8217;s Annual Report on Form 20-F and in the Management&#8217;s Discussion and Analysis for the three and nine months ended September 30, 2019 (copies of which may be obtained at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5_PSMLX1BOKQwtWOS3I_RYALtuHC-DL9iFUaxBFwOqZtPGgZ2iEdR4UM0WfsGVHvovQaA0VrYdqRGfEXYQ-7RQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.sedar.com<\/a>\u00a0or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5_PSMLX1BOKQwtWOS3I_RfljzECrgPemoCNPBhOBywzRZ0fINE_g7VMtKLpiI3ZgWKKMomopfotUESg1cSA00A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.sec.gov)<\/a>.\u00a0 These factors should be considered carefully, and readers should not place undue reliance on the Company&#8217;s forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzEyNyMzODMwMjQwIzUwMDA2ODg0Mw==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/c6de72df-e1a2-4695-8b2b-4c899f4d50ea\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>VANCOUVER, Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; via NewMediaWire \u2013 Neovasc, Inc.\u00a0(NASDAQ,\u00a0TSX: NVCN), today announced that company management will be participating in the Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum on Thursday, November 19, 2020.\u00a0 Fred Colen, Neovasc\u2019s President and Chief Executive Officer, will deliver a presentation at 11:00 am EST.\u00a0 Mr. Colen will also be joined by Chief Financial Officer Chris Clark, and Chief Operating Officer Bill Little, for investor meetings throughout the day. A link to the live webcast of the presentation will be available online from the investor relations section of the Neovasc website at\u00a0https:\/\/www.neovasc.com\/investors\/ About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-382316","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; via NewMediaWire \u2013 Neovasc, Inc.\u00a0(NASDAQ,\u00a0TSX: NVCN), today announced that company management will be participating in the Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum on Thursday, November 19, 2020.\u00a0 Fred Colen, Neovasc\u2019s President and Chief Executive Officer, will deliver a presentation at 11:00 am EST.\u00a0 Mr. Colen will also be joined by Chief Financial Officer Chris Clark, and Chief Operating Officer Bill Little, for investor meetings throughout the day. A link to the live webcast of the presentation will be available online from the investor relations section of the Neovasc website at\u00a0https:\/\/www.neovasc.com\/investors\/ About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular &hellip; Continue reading &quot;Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T21:36:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzEyNyMzODMwMjQwIzUwMDA2ODg0Mw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum\",\"datePublished\":\"2020-11-16T21:36:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\\\/\"},\"wordCount\":494,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzEyNyMzODMwMjQwIzUwMDA2ODg0Mw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\\\/\",\"name\":\"Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzEyNyMzODMwMjQwIzUwMDA2ODg0Mw==\",\"datePublished\":\"2020-11-16T21:36:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzEyNyMzODMwMjQwIzUwMDA2ODg0Mw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzEyNyMzODMwMjQwIzUwMDA2ODg0Mw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/","og_locale":"en_US","og_type":"article","og_title":"Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum - Market Newsdesk","og_description":"VANCOUVER, Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; via NewMediaWire \u2013 Neovasc, Inc.\u00a0(NASDAQ,\u00a0TSX: NVCN), today announced that company management will be participating in the Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum on Thursday, November 19, 2020.\u00a0 Fred Colen, Neovasc\u2019s President and Chief Executive Officer, will deliver a presentation at 11:00 am EST.\u00a0 Mr. Colen will also be joined by Chief Financial Officer Chris Clark, and Chief Operating Officer Bill Little, for investor meetings throughout the day. A link to the live webcast of the presentation will be available online from the investor relations section of the Neovasc website at\u00a0https:\/\/www.neovasc.com\/investors\/ About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular &hellip; Continue reading \"Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-16T21:36:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzEyNyMzODMwMjQwIzUwMDA2ODg0Mw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum","datePublished":"2020-11-16T21:36:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/"},"wordCount":494,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzEyNyMzODMwMjQwIzUwMDA2ODg0Mw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/","name":"Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzEyNyMzODMwMjQwIzUwMDA2ODg0Mw==","datePublished":"2020-11-16T21:36:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzEyNyMzODMwMjQwIzUwMDA2ODg0Mw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzEyNyMzODMwMjQwIzUwMDA2ODg0Mw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-to-participate-in-canaccord-genuity-2020-virtual-medtech-diagnostics-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech &amp; Diagnostics Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=382316"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382316\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=382316"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=382316"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=382316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}